or search on
|Title:||HPV vaccination and pregnancy|
|Categories:||Cancer Type - Cervical Cancer|
Prevention - Vaccines
|Journal Title:||British Medical Journal|
|Page number start:||h4705|
|Abstract:||Prophylactic vaccines against human papillomavirus (HPV) were first licensed for use in girls and young women in 2006, with more than 175 million doses distributed worldwide by 2013.1 Bivalent and quadrivalent vaccines protect against new infection with oncogenic HPV types 16 and 18, responsible for about 70% of cervical cancers. The quadrivalent vaccine also protects against HPV types 6 and 11, responsible for most anogenital warts. Although routine vaccination is recommended for preadolescent girls, catch-up to older ages was generally conducted in the first few years of implementation, with the upper age varying from 16-18 (United Kingdom, several European countries) to 23-26 years (France, Australia, United States). Although it is not recommended, many thousands of young women are thus likely to have been inadvertently vaccinated around the time of conception or in pregnancy.|
|Division:||Cancer Research Division|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.